Veda Giri, MD, Chief of Clinical Cancer Genetics and Co-Director of the Early Onset Cancer Program at Smilow Cancer Hospital and Yale Cancer Center, and Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), have been named Fellows of the American Society of Clinical Oncology (FASCO). The FASCO distinction honors members of ASCO for their extraordinary volunteer service, commitment, and dedication to the organization. Dr. Giri and Dr. Pusztai are two of 48 recipients nationwide to earn the FASCO designation.
Recipients have made exceptional contributions to the oncology community and this designation recognizes their commitment to transforming cancer care and improving quality of life for people living with cancer. As Director of the Early Onset Cancer Program, Dr. Giri focuses on cancers among people aged 18 to 49 and psychosocial needs, developing novel clinical care models, enhancing clinical trials, expanding research, and raising community awareness about early onset cancers. Dr. Pusztai cares for patients with breast cancer and is a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and has shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes.
ASCO represents nearly 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO furthers its mission through Cancer.Net and Conquer Cancer ®, the ASCO Foundation.